HAJIR DADGOSTAR, M.D., Ph.D.
Valley Retina Associates Medical Group, P.C.
16500 Ventura Blvd., Suite 250
Encino, CA 91436
Tel. 818-788-9333
Fax. 818-788-9273
CLINICAL PRACTICE
2009 - present Valley Retina Associates Medical Group, P.C. - Encino, CA
Physician - Vitreoretinal Surgery
ACADEMIC AFFILIATIONS
2010 - present West Los Angeles VA Medical Center - Los Angeles, CA
Volunteer Clinical Faculty - Vitreoretinal Surgery
2011 - present Jules Stein Eye Institute - UCLA - Los Angeles, CA
Clinical Instructor - Ophthalmology
HOSPITAL AFFILIATIONS
2009 - present Northridge Hospital Medical Center - Northridge, CA
Physician - Vitreoretinal Surgery
EDUCATION
1995 - 2003 UCLA School of Medicine - Medical Scientist Training Program -
Los Angeles, CA
Doctor of Medicine
May 2003
1997 - 2001 UCLA Molecular Biology Institute - Los Angeles, CA
Doctor of Philosophy in Molecular Biology
April 2001
1991 - 1995 University of California, Los Angeles Los Angeles, CA
Bachelor of Science in Psychobiology with Honors; Summa Cum Laude
March 1995
RESIDENCY TRAINING
2004 - 2007 Jules Stein Eye Institute - UCLA - Los Angeles, CA
Clinical Residency in Ophthalmology
2003 - 2004 Univeristy of Hawaii - Internal Medicine Residency Program - Honolulu, HI
Clinical Internship in Internal Medicine
FELLOWSHIP TRAINING
2007 - 2009 Cole Eye Institute - Cleveland Clinic Foundation - Cleveland, OH
Clinical Fellowship in Vitreoretinal Surgery
LICENSURE AND CERTIFICATIONS
2009 - present American Board of Ophthalmology - Diplomate (Active)
2007 - present State Medical Board of Ohio - Licensed Physician (Active)
2005 - present Medical Board of California - Licensed Physician (Active)
2005 - present US Department of Justice, DEA - Registered Practicioner (Active)
2003 - 2004 Hawaii DCCA, Medical Board - Licensed Physician in Training (Inactive)
PROFESSIONAL ASSOCIATIONS
2010 - present Los Angeles Society of Ophthalmology
2010 - present American Society of Retina Specialists
2009 - present California Academy of Eye Physicians and Surgeons
2007 - present Society of Heed Fellows
2004 - present American Medical Association
2004 - present American Academy of Ophthalmology
2003 - present Association for Research in Vision and Ophthalmology
HONORS/AWARDS
2009 Cole Eye Institute Fellow of the Year Award
2008 Annenberg Center Mentoring in Ophthalmology Fellows Program
2007 Fellow of the Society of Heed Fellows - Special Recognition
2007 Heed Foundation Fellowship Award
2007 Jules Stein Eye Institute Clinical Research Award
2006 Dr. Henry and Lilian Nesburn Award for Best Research Paper
2006 Pepose-Saltzman Young Investigator Award
2003 Emil Bogen Research Award
2003 California Endowment Scholar
2003 APSIH Young Scholar Award
2003 APSIH Recognition of Excellence in Medical Education
2002 Letter of Distinction - UCLA School of Medicine
2000 UCLA Dissertation Year Fellowship Award
1999 Warsaw Research Fellowship Award
1996 Letter of Distinction - UCLA School of Medicine
1995 Summa Cum Laude Graduate - UCLA
1994 Phi Beta Kappa National Honors Society
1992 Golden Key National Honors Society
1991 College Honors Scholar - UCLA (1991 - 1995)
1991 Dean’s Honors List - UCLA (1991 - 1995)
1991 UCLA Alumni Scholar
1991 UC Regents Scholar
ACADEMIC SERVICE
2009 - present Northridge Hospital Medical Center - Northridge, CA
Institutional review board (IRB)
RESEARCH AFFILIATIONS
2007 - 2009 Principal Investigator
Evaluation of the association between macular lesion morphology in age- related macular degeneration and the response to VEGF-inhibitor therapy.
Cole Eye Institute - Cleveland, OH
2009 Treating Clinical Investigator
VEGF TRAP-EYE Study: A phase III, double-masked, randomized study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age- related macular degeneration.
Cole Eye Institute - Cleveland, OH
2007 - 2009 Treating Clinical Investigator
DENALI Trial: A double-masked, randomized study evaluating combination verteporfin/ranibizumab therapy for exudative age-related macular degeneration.
Cole Eye Institute - Cleveland, OH
2007 - 2009 Treating Clinical Investigator
A study of the efficacy and safety of ranibizumab injection in patients with macular edema secondary to central retinal vein occlusion (CRUISE).
Cole Eye Institute - Cleveland, OH
2007 - 2009 Certified Reader
Digital Angiography Reading Center/Digital OCT Reading Center
Cole Eye Institute - Cleveland, OH
2007 - 2008 Treating Clinical Investigator
Anecortave Acetate Risk Reduction Trial (AART)
Cole Eye Institute - Cleveland, OH
2002 - 2007 Physician Researcher
Study of retinal blood flow abnormalities in HIV-positive individuals.
Jules Stein Eye Institute - Los Angeles, CA
1999 - 2000 Academic Collaborator
Global expression analysis in activated B lymphocytes.
Project proposal selected for collaboration in a nation-wide competitive application process.
Affymetrix, Inc., Academic User Center - Santa Clara, CA
1997 - 2001 Graduate Student Researcher
Molecular dissection of inflammatory intracellular signal transduction pathways.
UCLA Molecular Biology Institute - Los Angeles, CA
1996 Graduate Student Researcher
Study of CNS myelination through an immunological approach using antibodies that block myelin synthesis in vitro.
UCLA School of Medicine - Los Angeles, CA
1995 Graduate Student Researcher
Cloning of a gene involved in neuronal connectivity in Drosophila.
UCLA School of Medicine Department of Biological Chemistry/Howard Hughes Medical Institute - Los Angeles, CA
1993 - 1995 Undergraduate Student Researcher
Characterization of a polymorphic dinucleotide repeat within the human mu opioid receptor gene.
UCLA School of Medicine - Los Angeles, CA
REVIEW ARTICLES
Dadgostar, H. and Kaiser, P. K. 2009. siRNA Therapeutics for Age-related Macular Degeneration: Promises and Pitfalls. Exp Rev Ophthalmol. 4(5): 525-535.
Dadgostar, H. and Kaiser, P. K. 2009. Combination Therapies for Exudative AMD: A Look at Current Treatment Regimens and a Review of the Evidence. Rev Ophthalmol. 16(5): 72-78.
Dadgostar, H. and Waheed, N. 2008. The Evolving Role of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Neovascular Age-related Macular Degeneration. Eye. 22(6): 761-767.
Dadgostar, H. 2008. Safety, Efficacy, and Dosing Schedules for Ranibizumab in Exudative Age-related Macular Degeneration: A Comparative Review of Data from Multiple Clinical Trials. The Ophthalmology Report. 2(3): 13-19.
RESEARCH ARTICLES
Sachdeva, R., Dadgostar, H., Kaiser, P. K., Sears, J. E., Singh, A. D. 2010. Verteporfin Photodynamic Therapy of Six Eyes with Retinal Capillary Haemangioma. Acta Ophthalmol. 88(8): e334-340.
Dadgostar, H., Ventura, A. A. C. M., Chung, J., Sharma, S., Kaiser, P. K. 2009. Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration. Ophthalmology 116(9): 1740-1747.
Dadgostar, H., Holland, G. N., Huang, X., Tufail, A., Kim, A., Fisher, T. C., Cumberland, W. G., Meiselman, H. J., Benjamin, A. and Bartsch, D.-U. 2006. Hemorheologic Abnormalities Associated with HIV Infection: In Vivo Assessment of Retinal microvascular Blood Flow. Invest Ophthalmol Vis Sci. 47(9): 3933-3938.
Kim, A.,* Dadgostar, H.,* Holland, G. N., Wenby, R., Yu, F., Terry, B. G. and Meiselman, H. J. 2006. Hemorheologic Abnormalities Associated with HIV Infection: Altered Erythrocyte Aggregation and Deformability. Invest Ophthalmol Vis Sci. 47(9): 3927-3932.
*These authors contributed equally to this work
Dadgostar, H.,* Doyle, S. E.,* Shahangian, A.,* Garcia, D. E. and Cheng, G. 2003. T3JAM, a Novel Protein that Specifically Interacts with TRAF3 and Promotes the Activation of JNK(1). FEBS Lett. 553(3): 403-407.
*These authors contributed equally to this work
Doyle, S. E., Vaidya, S. A., O'Connell, R., Dadgostar, H., Dempsey, P. W., Wu, T., Rao, G., Sun, R., Haberland, M. E., Modlin, R. L. and Cheng, G. 2002. IRF3 Mediates a TLR3/TLR4-Specific
Anti-Viral Gene Program. Immunity. 17(3): 251-263.
Dadgostar, H., Zarnegar, B., Hoffmann, A., Qin, X.-F., Truong, U., Rao, G., Baltimore, D. and Cheng, G. 2002. Cooperation of Multiple Signaling Pathways in CD40-regulated Gene Expression in B Lymphocytes. Proc. Natl. Acad. Sci. USA. 99: 1497-1502.
Dadgostar, H. and Cheng, G. 2000. Membrane Localization of TRAF 3 Enables JNK Activation. J Biol Chem. 275(4): 2539-2544.
Lee, H.,* Dadgostar, H.,* Cheng, Q., Shu, J., and Cheng, G. 1999. NF-B-Mediated Up-Regulation of Bcl-x and Bfl-1/A1 is Required for CD40 Survival Signaling in B Lymphocytes. Proc. Natl. Acad. Sci. USA. 96: 9136-9141.
*These authors contributed equally to this work
Dadgostar, H. and Cheng, G. 1998. An Intact Zinc Ring Finger is Required for TRAF-mediated NF-B Activation but is Dispensable for JNK Signaling. J Biol Chem. 273(38): 24775-24780.
ABSTRACTS
Dadgostar, H., Ventura, A. A. C. M., Sharma, S., Chung, J., Kaiser, P. K. 2008. OCT Lesion Morphology and the Response of Exudative AMD to Ranibizumab. American Academy of Ophthalmology (Atlanta, GA).
Dadgostar, H., Ventura, A. A. C. M., Sharma, S., Chung, J., Kaiser, P. K. 2008. Early Lesion Morphology and Anatomic versus Functional Treatment Response to Ranibizumab Therapy for Exudative Age-Related Macular Degeneration. American Society of Retina Specialists (Maui, HI).
Dadgostar, H., Silveira, C., Jones, J. L., Lee, G., Muccioli, C., Belfort, R., Holland, G. N. 2008. Risk Factors for Ocular Toxoplasmosis Among Individuals Recently Infected by Toxoplasma gondii in Southern Brazil. Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).
Dadgostar, H., Holland, G. N., Huang, X., Tufail, A., Kim, A., Fisher, T. C., Cumberland, W. G., Meiselman, H. J., Benjamin, A. and Bartsch, D.-U. 2006. A Relationship Between Altered in vivo Retinal Microvascular Blood Flow and Leukocyte Rigidity in HIV-Infected Individuals. Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).
Kim, A., Dadgostar, H., Holland, G. N., Wenby, R. B., Yu, F. and Meiselman, H. J. 2003. Hemorheologic Abnormalities in HIV-Infected Individuals with CD4+ T-lymphocyte Counts >200/L. Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).
Vaidya, S. A., Doyle, S. E., O'Connell, R., Dadgostar, H., Dempsey, P. W., Wu, T., Rao, G., Sun, R., Haberland, M. E., Modlin, R. L. and Cheng, G. 2003. The Role of IRF3 in TLR-Specific Gene Expression in Macrophages. Keystone Symposia (Taos, NM).
Dadgostar, H., Zarnegar, B. and Cheng, G. 2000. A Global Analysis of CD40- and LPS-Mediated Gene Regulation in B Lymphocytes. National MD/PhD Student Conference (Aspen, CO).
Dadgostar, H. and Cheng, G. 1999. The Roles of TRAF Structure and Subcellular Localization in the Activation of Downstream Signaling. Keystone Symposia (Keystone, CO).
Keith, D., Evans, C., Tian, J., Wen, C., Tran, T., Dadgostar, H., Phan, T., Anton, B., Magenzo, K., Zaki, P., Maung, T., and Kaufman, D. 1994. Characterization of a Mouse Mu Opioid Receptor. International Narcotics Research Conference (Cape Cod, MA).
Kaufman, D. L., Selleri, L., Ting, G. S. P., Newman, D., Keith, D., Phan, T., Tian, J., Tran, T., Dadgostar, H., Giovannini, M., Evans, C. J., and Barchas, J. D. 1993. Characterization of the Human Delta Opioid Receptor Gene. Society for Neuroscience (Washington D.C.).
DOCTORAL DISSERTATION
Dadgostar, H. A Multi-Level Dissection of CD40-Activated Intracellular Signal Transduction Pathways. Copyright by H. Dadgostar. 2001.
BOOK CHAPTERS
Dadgostar, H., Ventura, A. A. C. M., and Hayden, B. C. Posterior Segment Trauma. In Ultrasound Clinics: Ophthalmic Ultrasound?. 3(2): 267-272. 2008. Eds. Singh, A. D., Hayden, B. C. and Pavlin, C. J. Elsevier Science.
Dadgostar, H. and Kaiser, P. K. PDT and Combination Treatment with PDT and AMD. In Macular Degeneration: State of the Art. 2008. Remedica Publishing, London. (In Press)
Dadgostar, H. and Kaiser, P. K. Anecortave Acetate. In Retinal Pharmacotherapy, 1st Edition. 2008. Eds. Nguyen, Q. D., Rodrigues, E. B., Farah, M. E., and Mieler, W. F. Elsevier Science. (In press)
Dadgostar, H. and Singh, A. D. Retinal Vascular Tumors. In Encyclopedia of Ophthalmology: Ophthalmic Pathology and Ocular Tumors. 2008. Eds. Schmidt-Erfurth, U., Mieler, W. F., Williams, G. A. Springer Verlag. (In Press)
Dadgostar, H. and Kaiser, P. K. How Should I Follow Diabetic Macular Edema and When Does it Require Treatment? In Curbside Consultation in Retina. 2008. Eds. Fekrat, S., Moshfeghi, D., Eliott, D. and Haller, J. Slack, Inc. (In Press)
LECTURE PRESENTATIONS
January 12, 2010—“Diabetic Eye Disease”; Beverly Hills Iranian American Doctors Association (Beverly Hills, CA).
June 19, 2009—“‘As Needed’ Ranibizumab Monotherapy in Neovascular AMD: An Analysis of Variables Related to Visual Outcomes”; Cole Eye Institute Research and Alumni Program (Cleveland, OH).
June 13, 2008—“Morphologic Analysis of Macular Lesion Changes in OCT-guided Ranibizumab Monotherapy for Exudative AMD”; Cole Eye Institute Research and Alumni Program (Cleveland, OH).
May 18, 2007—“Risk Factors for Ocular Toxoplasmosis among Individuals Recently Infected by Toxoplasma gondii in southern Brazil”; Jules Stein Eye Institute Clinical Research Seminar (UCLA).
May 21, 2005—“Hemorheologic Abnormalities in HIV-Infected Individuals”; Jules Stein Eye Institute Clinical Research Seminar (UCLA).
June 18, 2001—“Overlapping and Stimulus-Specific Global Activation Responses of Resting B Cells to CD40L and LPS”; CalTech-UCLA Joint Seminar on Signaling and Gene Expression (UCLA).
October 3, 2000—“Use of High-Density DNA Microarrays for a Global-Scale Analysis of CD40 Ligand- and Lipopolysaccharide-Mediated Activation of B Cells”; Access Gene Expression Affinity Group Seminar Series (UCLA).
September 18, 2000—“Overlapping and Stimulus-Specific Global Activation Responses of Resting B Cells to CD40L and LPS”; The Institute for Pure and Applied Mathematics (UCLA).
September 8, 2000—“Use of High-Density DNA Microarrays for a Global-Scale Analysis of CD40 Ligand- and Lipopolysaccharide-Mediated Activation of B Cells”; UCLA Medical Scientist Training Program Annual Retreat (Lake Arrowhead, CA).
June 28, 2000—“Dissecting Differential B Cell Activation Responses to CD40 Ligand and LPS through Global Gene Expression Analysis”; UCLA Dept. of Microbiology and Molecular Genetics Annual Warsaw Scholars’ Luncheon (UCLA).
November 12, 1998—“An Intact Zinc Ring Finger is Required for TRAF-mediated NF-B Activation but is Dispensable for JNK Signaling”; Jonsson Comprehensive Cancer Center Seminar Series (UCLA).
October 24, 1998—“An Intact Zinc Ring Finger is Required for TRAF-mediated NF-B Activation but is Dispensable for JNK Signaling”; UCLA Molecular Biology Institute Annual Retreat (Lake Arrowhead, CA).
September 12, 1998—“Distinct Structural Requirements for TRAF-mediated NF-B Activation vs. JNK Activation”; UCLA Medical Scientist Training Program Annual Retreat (Lake Arrowhead, CA).
POSTER PRESENTATIONS
November 8, 2008—“OCT Lesion Morphology and the Response of Exudative AMD to Ranibizumab”; American Academy of Ophthalmology (Atlanta, GA).
October 12, 2008—“Early Lesion Morphology and Anatomic versus Functional Treatment Response to Ranibizumab Therapy for Exudative Age-Related Macular Degeneration”; American Society of Retina Specialists (Maui, HI).
May 1, 2008—“ Risk Factors for Ocular Toxoplasmosis Among Individuals Recently Infected by Toxoplasma gondii in Southern Brazil”; Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).
May 2, 2006—“A Relationship Between Altered in vivo Retinal Microvascular Blood Flow and Leukocyte Rigidity in HIV-Infected Individuals”, Association for Research in Vision and Ophthalmology (Ft. Lauderdale, FL).
March 21, 2003—“T2-2, A Novel TRAF3-Interacting Protein Involved in JNK Signaling”, (David Geffen School of Medicine Poster Day (UCLA).
April 11, 2001—“Cooperation of Multiple Signaling Pathways in CD40-regulated Gene Expression in B Lymphocytes”, UCLA Medical Scientist Training Program Poster Day (UCLA).
July 15, 2000—“A Global Analysis of CD40- and LPS-Mediated Gene Regulation in B Lymphocytes”; National MD/PhD Student Conference (Aspen, CO).
November 5, 1999—“Multiple Approaches to the Systematic Identification of CD40-regulated Genes”, “The Roles of TRAF Structure and Subcellular Localization in the Activation of Downstream Signaling”; UCLA Jonsson Comprehensive Cancer Center Symposium (UCLA).
September 17, 1999—“Multiple Approaches to the Systematic Identification of CD40-regulated Genes”; UCLA Medical Scientist Training Program Annual Retreat (Lake Arrowhead, CA).
May 10, 1999—“The Roles of TRAF Structure and Subcellular Localization in the Activation of Downstream Signaling”; UCLA Signal Transduction Symposium (UCLA).
April 12, 1999—“The Roles of TRAF Structure and Subcellular Localization in the Activation of Downstream Signaling”; Keystone Symposia: Specificity in Signal Transduction (Keystone, CO).
